NO953353L - Xantinderivater som adenosin-A -reseptorantagonister - Google Patents
Xantinderivater som adenosin-A -reseptorantagonisterInfo
- Publication number
- NO953353L NO953353L NO953353A NO953353A NO953353L NO 953353 L NO953353 L NO 953353L NO 953353 A NO953353 A NO 953353A NO 953353 A NO953353 A NO 953353A NO 953353 L NO953353 L NO 953353L
- Authority
- NO
- Norway
- Prior art keywords
- adenosine
- pct
- receptor antagonists
- xanthine derivatives
- sec
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2350193A | 1993-02-26 | 1993-02-26 | |
| PCT/US1994/001009 WO1994019349A1 (en) | 1993-02-26 | 1994-01-27 | Xanthine derivatives as adenosine a1 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO953353D0 NO953353D0 (no) | 1995-08-25 |
| NO953353L true NO953353L (no) | 1995-08-25 |
| NO311920B1 NO311920B1 (no) | 2002-02-18 |
Family
ID=21815459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19953353A NO311920B1 (no) | 1993-02-26 | 1995-08-25 | Xantinderivater som adenosin-A1-reseptorantagonister |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5840729A (no) |
| EP (1) | EP0686155B1 (no) |
| JP (1) | JPH08512281A (no) |
| KR (1) | KR100315898B1 (no) |
| CN (1) | CN1041418C (no) |
| AT (1) | ATE169019T1 (no) |
| AU (1) | AU680241B2 (no) |
| CA (1) | CA2155130C (no) |
| DE (1) | DE69412073T2 (no) |
| DK (1) | DK0686155T3 (no) |
| ES (1) | ES2120025T3 (no) |
| HU (1) | HUT72677A (no) |
| IL (1) | IL108750A (no) |
| MX (1) | MX9401406A (no) |
| NO (1) | NO311920B1 (no) |
| NZ (1) | NZ262984A (no) |
| TW (1) | TW261532B (no) |
| WO (1) | WO1994019349A1 (no) |
| ZA (1) | ZA941176B (no) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998041237A1 (fr) * | 1997-03-18 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Medicaments pour la prevention et la therapie de l'hyperphosphatemie |
| BR9911612A (pt) | 1998-06-02 | 2001-02-06 | Osi Pharm Inc | Composições de pirrolo[2,3d]pirimidina e seus usos |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
| JP2005529062A (ja) | 2001-11-30 | 2005-09-29 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アデノシンａ１及びａ３受容体に特異的な化合物とその使用 |
| EP1465631B1 (en) | 2001-12-20 | 2010-02-24 | OSI Pharmaceuticals, Inc. | Pyrimidine a2b selective antagonist compounds, their synthesis and use |
| ATE415387T1 (de) * | 2002-05-15 | 2008-12-15 | Genzyme Corp | Verfahren zur herstellung von benzonitrilen und benzimidosäure-derivaten |
| WO2004086047A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) |
| JPWO2005056016A1 (ja) * | 2003-12-09 | 2007-07-05 | 協和醗酵工業株式会社 | 高次脳機能障害の予防および／または治療剤 |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8817122U1 (de) * | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| JPH0455150A (ja) * | 1990-06-22 | 1992-02-21 | Takata Kk | 助手席用エアバッグ装置 |
| US5087827A (en) * | 1991-02-11 | 1992-02-11 | Tektronix, Inc. | Variable voltage transition circuit |
| US5208240A (en) * | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1994
- 1994-01-27 DE DE69412073T patent/DE69412073T2/de not_active Expired - Fee Related
- 1994-01-27 DK DK94910661T patent/DK0686155T3/da active
- 1994-01-27 NZ NZ262984A patent/NZ262984A/en unknown
- 1994-01-27 CA CA002155130A patent/CA2155130C/en not_active Expired - Fee Related
- 1994-01-27 ES ES94910661T patent/ES2120025T3/es not_active Expired - Lifetime
- 1994-01-27 AT AT94910661T patent/ATE169019T1/de not_active IP Right Cessation
- 1994-01-27 HU HU9502495A patent/HUT72677A/hu unknown
- 1994-01-27 JP JP6518986A patent/JPH08512281A/ja active Pending
- 1994-01-27 CN CN94191309A patent/CN1041418C/zh not_active Expired - Fee Related
- 1994-01-27 AU AU62968/94A patent/AU680241B2/en not_active Ceased
- 1994-01-27 KR KR1019950703577A patent/KR100315898B1/ko not_active IP Right Cessation
- 1994-01-27 WO PCT/US1994/001009 patent/WO1994019349A1/en active IP Right Grant
- 1994-01-27 US US08/500,991 patent/US5840729A/en not_active Expired - Fee Related
- 1994-01-27 EP EP94910661A patent/EP0686155B1/en not_active Expired - Lifetime
- 1994-02-21 ZA ZA941176A patent/ZA941176B/xx unknown
- 1994-02-22 TW TW083101485A patent/TW261532B/zh active
- 1994-02-23 IL IL10875094A patent/IL108750A/xx not_active IP Right Cessation
- 1994-02-24 MX MX9401406A patent/MX9401406A/es not_active IP Right Cessation
-
1995
- 1995-08-25 NO NO19953353A patent/NO311920B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2120025T3 (es) | 1998-10-16 |
| JPH08512281A (ja) | 1996-12-24 |
| CA2155130C (en) | 1994-09-01 |
| NO311920B1 (no) | 2002-02-18 |
| CA2155130A1 (en) | 1994-09-01 |
| ZA941176B (en) | 1994-09-20 |
| KR100315898B1 (ko) | 2002-02-28 |
| NZ262984A (en) | 1997-05-26 |
| DE69412073D1 (de) | 1998-09-03 |
| AU6296894A (en) | 1994-09-14 |
| US5840729A (en) | 1998-11-24 |
| TW261532B (no) | 1995-11-01 |
| IL108750A (en) | 2000-09-28 |
| AU680241B2 (en) | 1997-07-24 |
| WO1994019349A1 (en) | 1994-09-01 |
| DE69412073T2 (de) | 1999-02-18 |
| HUT72677A (en) | 1996-05-28 |
| IL108750A0 (en) | 1994-05-30 |
| CN1041418C (zh) | 1998-12-30 |
| HU9502495D0 (en) | 1995-10-30 |
| EP0686155A1 (en) | 1995-12-13 |
| EP0686155B1 (en) | 1998-07-29 |
| NO953353D0 (no) | 1995-08-25 |
| DK0686155T3 (da) | 1999-02-01 |
| CN1118599A (zh) | 1996-03-13 |
| ATE169019T1 (de) | 1998-08-15 |
| MX9401406A (es) | 1994-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69622031D1 (de) | INDOLDERIVATE ALS cGMP-PDE INHIBITOREN | |
| ATE188379T1 (de) | Fibrinogenrezeptor-antagonisten | |
| NO960630D0 (no) | Heterocykler anvendelige som neurokinin antagonister | |
| DK0687268T3 (da) | Spiroazacykliske derivater som substans P-antagonister | |
| ES2091689T3 (es) | Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos. | |
| DE69530081D1 (de) | Gastrin- und cck-antagonisten | |
| ES2121193T3 (es) | Derivados de bencimidazoles. | |
| DE69611377D1 (de) | 1,2,4-triazolo[1,5-c]pyrimidin-heterocyclische analoge mit antagonistischer aktivität auf dem adenosine a2a rezeptor | |
| NO953353L (no) | Xantinderivater som adenosin-A -reseptorantagonister | |
| TR199900501T2 (xx) | Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�. | |
| ATE113056T1 (de) | Künstliche rezeptor-analoge. | |
| ES2145772T3 (es) | Uso de un complejo de ibuprofeno-beta-ciclodextrina para administracion oral. | |
| ATE189894T1 (de) | Naphthamidderivate von 3-beta-amino azabicyclooctan oder nonan als antipsychotische arzneimittel | |
| ES2162078T3 (es) | Compuestos terapeuticos. | |
| GR3024854T3 (en) | Drugs for preventing the development of tolerance during treatment with benzodiazepine-receptor-binding substances. | |
| PL311296A1 (en) | Derivatives of benzo [f] quinoxalinodione, method of obtaining them and their application in therapeutic agents | |
| PT958290E (pt) | Derivados de 1,4-di-hidropiridina e seu uso em terapia | |
| KR960700053A (ko) | 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer) | |
| ITMI950956A0 (it) | Uso degli enantiomeri (s) di derivati 1,4-diidropiridinici per il trattamento dell'insufficienza cardiaca | |
| ATE221068T1 (de) | Anellierte beta-carboline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |